MFDS approves 'Ribtensity' for cytomegalovirus treatment
[Asia Economy Reporter Lee Gwan-joo] The Ministry of Food and Drug Safety announced on the 28th that it has approved Livtencity Tablets (Maribavir), a treatment for post-transplant cytomegalovirus (CMV) infection, a rare drug from Korea Takeda Pharmaceutical.
Cytomegalovirus remains in an asymptomatic latent state after infection, but when immunity is weakened due to organ transplantation, the virus reactivates and causes serious diseases.
Livtencity Tablets are oral antiviral agents that inhibit viral replication by reducing the activity of the UL97 protein kinase enzyme involved in the replication and proliferation of cytomegalovirus.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- U.S. Treasury Secretary: "30-Day Temporary License for Russian Crude Oil Transactions"
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
It is expected to provide a new treatment opportunity for adult patients with post-transplant cytomegalovirus infection who are resistant or non-responsive to one or more existing antiviral drugs such as ganciclovir, valganciclovir, foscarnet, and cidofovir.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
